Reprint

Updates on Breast Cancer

Edited by
May 2024
320 pages
  • ISBN978-3-7258-0389-7 (Hardback)
  • ISBN978-3-7258-0390-3 (PDF)

This book is a reprint of the Special Issue Updates on Breast Cancer that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

"Updates on Breast Cancer" is a comprehensive collection published as a Cancers’ Special Issue that delves into the latest breast cancer research and treatment developments. With a focus on precision medicine, innovative technologies, and personalized patient care, this collection of 18 articles presents a wealth of knowledge and insights for the medical community engaged in breast cancer research and patient care. Breast cancer, one of the most prevalent malignancies globally, continues to be a challenging health concern. In this Special Issue, esteemed experts in the field collaborate to explore diverse aspects of breast cancer, ranging from diagnostics to postoperative surveillance. The aim is to equip healthcare professionals with the tools and information they need to make informed decisions and provide optimal care for breast cancer patients. As readers explore the studies included in the Special Issue "Updates on Breast Cancer," they can discover the remarkable progress achieved through collective efforts, technological innovation, and unwavering commitment. We invited the medical community to embrace these advancements as we work together toward a brighter and more promising future in the fight against breast cancer.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
ductal carcinoma in situ (DCIS); invasive breast carcinoma; breast; biopsy; overtreatment; active surveillance; Contrast-Enhanced Mammography (CEM); Dynamic Contrast Magnetic Resonance Imaging (DCE-MRI); radiomics; artificial intelligence; breast tumor segmentation; convolutional neural network; deep learning; X-ray images; breast cancer; brain metastasis; tissue-specific metastasis; organotropism; cancer metabolism; oxidative phosphorylation (OXPHOS); mitochondria; cyclooxygenase 7b (Cox7b); hereditary breast cancer; cancer susceptibility genes; PALB2; aberrant splicing; functional assay; minigenes; clinical interpretation; breast cancer; cyclin-dependent kinase inhibitor 4 and 6; HER2-low; palbociclib; circulating tumor cells; neoplastic cells; circulating; neoplasms/diagnosis; circulating/pathology; biopsy; breast neoplasms/pathology; biomarkers; tumor; blood; liquid biopsy; AhR; breast cancer; agonist; ligand; TCDD; triple-negative breast cancer; exploratory subgroup discovery; chemoimmunotherapy; breast cancer; bone metastases; bone scan; follow-up; prognosis; survival; SETD7; breast cancer; molecular subtypes; survival; gene expression; biological processes; HER2; breast cancer; HER2-low; antibody-drug conjugate; trastuzumab-deruxtecan; T-Dxd; artificial intelligence; communication; decision-making; patient empowerment; ONEST; observers needed to evaluate subjective tests; TILs; sTILs; tumour-infiltrating lymphocytes; triple-negative; breast cancer; reproducibility; international immuno-oncology biomarker working group; European Working Group for Breast Screening Pathology; breast cancer; breast-conserving surgery; radiation; de-escalation; biomarkers; prognosis; breast cancer; early breast cancer; metastatic breast cancer; BRCA; NGS; HRD score; homologous recombination deficiency; mutational signature; PARPi; platinum salts; n/a; metastasis; secretome; immune modulation; tumor microenvironment; drug resistance; therapeutic targets; precision oncology; n/a